Search results for " Genetica"

showing 10 items of 659 documents

Caffeine boosts Ataluren's readthrough activity

2019

Abstract The readthrough of nonsense mutations by small molecules like Ataluren is considered a novel therapeutic approach to overcome the gene defect in several genetic diseases as cystic fibrosis (CF). This pharmacological approach suppresses translation termination at premature termination codons (PTCs readthrough) thus restoring the expression of a functional protein. However, readthrough might be limited by the nonsense-mediated mRNA decay (NMD), a cell process that reduces the amount/level of PTCs containing mRNAs. Here we investigate the combined action of Ataluren and caffeine to enhance the readthrough of PTCs. IB3.1 CF cells with a nonsense mutation were treated with caffeine to a…

0301 basic medicineMolecular biologymedia_common.quotation_subjectCellNonsenseNonsense mutationMRNA DecaySettore BIO/11 - Biologia MolecolareBiochemistryCystic fibrosisArticleCystic fibrosisCFTR gene03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCaffeinemedicinelcsh:Social sciences (General)Settore BIO/06 - Anatomia Comparata E Citologialcsh:Science (General)media_commonMessenger RNAMultidisciplinaryNonsense mutationNonsense mutationsPTC readthroughAtaluren/PTC124Settore CHIM/06 - Chimica Organicamedicine.diseaseCell biologyAtalurenSettore BIO/18 - Genetica030104 developmental biologymedicine.anatomical_structurechemistryCystic fibrosilcsh:H1-99Caffeine030217 neurology & neurosurgerylcsh:Q1-390Heliyon
researchProduct

Drosophila SMN2minigene reporter model identifies moxifloxacin as a candidate therapy for SMA

2018

Spinal muscular atrophy is a rare and fatal neuromuscular disorder caused by the loss of alpha motor neurons. The affected individuals have mutated the ubiquitously expressed SMN1 gene resulting in the loss or reduction in the survival motor neuron (SMN) protein levels. However, an almost identical paralog exists in humans: SMN2. Pharmacological activation of SMN2 exon 7 inclusion by small molecules or modified antisense oligonucleotides is a valid approach to treat SMA. Here we describe an in vivo SMN2 minigene reporter system in Drosophila motor neurons that serves as a cost-effective, feasible, and stringent primary screening model for identifying chemicals capable of crossing the conser…

0301 basic medicineMoxifloxacinDrug Evaluation PreclinicalSMN1BiologyBiochemistryAnimals Genetically ModifiedMuscular Atrophy Spinal03 medical and health sciencesExon0302 clinical medicineGenes ReporterGeneticsmedicineAnimalsHumansMolecular BiologyExonsSpinal muscular atrophyMotor neuronSMA*medicine.diseasenervous system diseasesCell biologySurvival of Motor Neuron 2 ProteinAlternative SplicingDisease Models AnimalDrosophila melanogaster030104 developmental biologymedicine.anatomical_structureCajal bodyBlood-Brain BarrierRNA splicing030217 neurology & neurosurgeryBiotechnologyMinigeneThe FASEB Journal
researchProduct

Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients

2016

In the last 20 years, following the identification of the BRCA1 and BRCA2 genes (hereinafter referred to as the BRCA genes), preventive pathways have been developed for the identification and clinical management of individuals at high risk of developing breast and ovarian cancer due to the presence of a pathogenic variant in either of these genes. These pathways are aimed at educating high-risk subjects on programs targeted toward early diagnosis and cancer risk reduction. The approval of a novel class of drugs, the PARP enzyme inhibitors, for the treatment of ovarian cancer patients carrying high-risk BRCA pathogenic variants has changed this scenario. BRCA testing, in addition to providin…

0301 basic medicineOncologyCancer ResearchGenes BRCA2Genes BRCA1Brca testingBRCA1; BRCA2; genetic testing; germline mutations; ovarian cancer; PARP inhibitors; somatic mutations; Oncology; Cancer ResearchSettore MED/03 - GENETICA MEDICA0302 clinical medicineClinical decision makingInformed consentsomatic mutationBRCA1 BRCA2 genetic testing germline mutations somatic mutations ovarian cancer PARP inibitorsDisease management (health)PARP inhibitorsOvarian NeoplasmsTumorInformed Consentmedicine.diagnostic_testDisease ManagementGeneral MedicinePrognosisBRCA1; BRCA2; genetic testing; germline mutations; ovarian cancer; PARP inhibitors; somatic mutations; Biomarkers Tumor; Clinical Decision-Making; Disease Management; Female; Genes BRCA1; Genetic Variation; Germ-Line Mutation; Humans; Informed Consent; Mutation; Ovarian Neoplasms; Prognosis; Genes BRCA2; Genetic Testing; Oncology; Cancer Researchovarian cancergermline mutationOncology030220 oncology & carcinogenesisgermline mutationsFemaleHumanmedicine.medical_specialtyPrognosiClinical Decision-MakingMEDLINEgenetic testing03 medical and health sciencesPARP inibitorsInternal medicinemedicineBiomarkers TumorHumansGerm-Line MutationGenetic testingGynecologyBRCA1; BRCA2; PARP inhibitors; genetic testing; germline mutations; ovarian cancer; somatic mutationsbusiness.industryOvarian NeoplasmGenetic Variationmedicine.diseaseBRCA1BRCA2030104 developmental biologyPARP inhibitorGenesMutationsomatic mutationsOvarian cancerbusinessBiomarkers
researchProduct

Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives

2019

The current availability of new Poly(ADP-ribose) Polymerase (PARP)-inhibitors for the treatment of ovarian cancer patients independently of the presence of a BRCA pathogenic variant, together with the validation of somatic test for the analysis of BRCA1/2 genes, involves the need to optimise the guidelines for BRCA testing. The AIOM-SIGU-SIBIOC-SIAPEC-IAP Italian Scientific Societies, in this position paper, recommend the implementation of BRCA testing with 2 main objectives: the first is the identification of ovarian cancer patients with higher probability of benefit from specific anticancer treatments (test for response to therapy); the second goal, through BRCA testing in the family memb…

0301 basic medicineOncologyGenetic testingendocrine system diseasesSettore MED/03 - GENETICA MEDICAMedical OncologyBiochemistrychemistry.chemical_compound0302 clinical medicineGermline mutationPARP inhibitorsTrabectedinSocieties MedicalOvarian Neoplasmsmedicine.diagnostic_testBRCA1 ProteinHematologyfemale genital diseases and pregnancy complicationsOncologyItaly030220 oncology & carcinogenesisFemalemedicine.drugHumanmedicine.medical_specialtyGenetic counselingOlaparib03 medical and health sciencesGeneticSomatic mutationsOvarian cancerMedicalInternal medicineBRCA1; BRCA2; Genetic testing; Germline mutations; Ovarian cancer; PARP inhibitors; Somatic mutations; BRCA1 Protein; BRCA2 Protein; Biochemistry; Female; Genetic Testing; Genetics; Humans; Italy; Medical Oncology; Ovarian Neoplasms; Germ-Line Mutation; Societies MedicalGeneticsmedicineGenetic predispositionHumansRucaparibGermline mutationsGerm-Line MutationGenetic testingBRCA2 Proteinbusiness.industrySomatic mutationOvarian NeoplasmCancermedicine.diseaseBRCA1BRCA2BRCA1; BRCA2; Genetic testing; Germline mutations; Ovarian cancer; PARP inhibitors; Somatic mutations030104 developmental biologyPARP inhibitorchemistrySocietiesOvarian cancerbusiness
researchProduct

Mid-region parathyroid hormone-related protein is a genome-wide chromatin-binding factor that promotes growth and differentiation of HB2 epithelial c…

2018

Human parathyroid hormone-related protein (PTHrP) is a polyhormone that undergoes proteolytic cleavage producing smaller peptides which exert diversified biological effects. PTHrP signalization is prominently involved in breast development and physiology, but the studies have been focused onto either N-terminal species or full-length protein introduced by gene transfer techniques. Our present work investigates for the first time the effect of the mid-region PTHrP secretory form, that is, the fragment [38-94], on HB2 non-tumoral breast epithelial cells. We examined viability/proliferation of cells grown in PTHrP-containing media supplemented with different serum concentration and on differen…

0301 basic medicinePTHrPCellClinical BiochemistryBiochemistryCell Line03 medical and health sciences0302 clinical medicineCell Line TumorGene expressionmedicineHumanscell growthBinding siteSettore BIO/06 - Anatomia Comparata E CitologiaCell ProliferationParathyroid hormone-related proteinChemistryCell growthChromatin bindingParathyroid Hormone-Related ProteinCell DifferentiationEpithelial CellsGeneral MedicineChromatinCell biologychromosome decorationSettore BIO/18 - Genetica030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisbreast cellgene expressionMolecular MedicineFemaleReprogramminghormones hormone substitutes and hormone antagonists
researchProduct

Modulating allergic response by engineering the major Parietaria allergens.

2017

0301 basic medicineParietariaImmunologySettore BIO/11 - Biologia MolecolareBiologyAllergensAntigens Plantmedicine.disease_causebiology.organism_classificationPlants Genetically Modified03 medical and health sciencesDisease Models AnimalMice030104 developmental biology0302 clinical medicineParietaria030228 respiratory systemAllergic responseImmunologymedicineHypersensitivityImmunology and AllergyAnimalsHumansPlant ProteinsThe Journal of allergy and clinical immunology
researchProduct

Identification of potential therapeutic compounds for Parkinson's disease using Drosophila and human cell models.

2017

Abstract Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease. It is caused by a loss of dopaminergic neurons in the substantia nigra pars compacta, leading to a decrease in dopamine levels in the striatum and thus producing movement impairment. Major physiological causes of neurodegeneration in PD are oxidative stress (OS) and mitochondrial dysfunction; these pathophysiological changes can be caused by both genetic and environmental factors. Although most PD cases are sporadic, it has been shown that 5–10% of them are familial forms caused by mutations in certain genes. One of these genes is the DJ-1 oncogene, which is involved in an early…

0301 basic medicineParkinson's diseaseProtein Deglycase DJ-1Drug Evaluation PreclinicalSubstantia nigraNerve Tissue ProteinsBiologymedicine.disease_causeBiochemistryAnimals Genetically Modified03 medical and health sciences0302 clinical medicineDopaminePhysiology (medical)Cell Line TumorDrug DiscoverymedicineAnimalsDrosophila ProteinsHumansGeneticsMutationPars compactaNeurodegenerationDopaminergicParkinson Diseasemedicine.diseaseDisease Models AnimalOxidative Stress030104 developmental biologyGene Knockdown TechniquesMutationCancer researchDrosophila030217 neurology & neurosurgeryOxidative stressLocomotionmedicine.drugFree radical biologymedicine
researchProduct

A multiomics analysis of S100 protein family in breast cancer

2018

The S100 gene family is the largest subfamily of calcium binding proteins of EF-hand type, expressed in tissue and cell-specific manner, acting both as intracellular regulators and extracellular mediators. There is a growing interest in the S100 proteins and their relationships with different cancers because of their involvement in a variety of biological events closely related to tumorigenesis and cancer progression. However, the collective role and the possible coordination of this group of proteins, as well as the functional implications of their expression in breast cancer (BC) is still poorly known. We previously reported a large-scale proteomic investigation performed on BC patients f…

0301 basic medicinePathway analysiBiologyProteomicsmedicine.disease_causeBreast cancer; Expression analysis; Pathway analysis; Proteomics; S100 proteins; OncologyTranscriptome03 medical and health sciencesproteomics0302 clinical medicineBreast cancerBreast cancerExpression analysiSettore BIO/13 - Biologia ApplicataCalcium-binding proteinmedicineGene familyexpression analysisSettore BIO/06 - Anatomia Comparata E CitologiaCancerProteomicmedicine.diseasePhenotypepathway analysisS100 proteinSettore BIO/18 - Genetica030104 developmental biologyOncology030220 oncology & carcinogenesisCancer researchCarcinogenesisS100 proteinsResearch Paper
researchProduct

Copper transporter COPT5 participates in the crosstalk between vacuolar copper and iron pools mobilisation

2019

Copper (Cu) deficiency affects iron (Fe) homeostasis in several plant processes, including the increased Fe requirements due to cuproprotein substitutions for the corresponding Fe counterpart. Loss-of-function mutants from Arabidopsis thaliana high affinity copper transporter COPT5 and Fe transporters NATURAL RESISTANCE-ASSOCIATED MACROPHAGE PROTEIN 3/4 (NRAMP3 and NRAMP4) were used to study the interaction between metals internal pools. A physiological characterisation showed that the copt5 mutant is sensitive to Fe deficiency, and that nramp3nramp4 mutant growth was severely affected under limiting Cu. By a transcriptomic analysis, we observed that NRAMP4 expression was highly induced in …

0301 basic medicinePhysiologyIron[SDV]Life Sciences [q-bio]MutantArabidopsislcsh:Medicinechemistry.chemical_elementChromosomal translocationVacuolePlant RootsArticleMetal03 medical and health sciences0302 clinical medicineCopper Transport ProteinsGene Expression Regulation PlantMetalloproteinHomeostasis[SDV.BV]Life Sciences [q-bio]/Vegetal BiologySLC31 Proteinslcsh:ScienceComputingMilieux_MISCELLANEOUSchemistry.chemical_classificationMultidisciplinaryArabidopsis Proteinslcsh:RBiological TransportTransporterPlants Genetically ModifiedCopperCrosstalk (biology)030104 developmental biologychemistryMetalsvisual_artVacuolesvisual_art.visual_art_mediumBiophysicslcsh:QPlant sciences[SDV.AEN]Life Sciences [q-bio]/Food and NutritionCopper030217 neurology & neurosurgeryScientific Reports
researchProduct

Aβ Induces Excitotoxicity Mediated by APC/C-Cdh1 Depletion That Can Be Prevented by Glutaminase Inhibition Promoting Neuronal Survival

2016

AbstractThe E3 ubiquitin ligase anaphase-promoting complex/cyclosome (APC/C) is activated by the fizzy-related protein homolog/CDC20-like protein 1 (cdh1) in post-mitotic neurons. Growing evidence suggests that dysregulation of APC/C-Cdh1 is involved in neurodegenerative diseases. Here we show in neurons that oligomers of amyloid beta (Aβ), a peptide related to Alzheimer’s disease, cause proteasome-dependent degradation of cdh1. This leads to a subsequent increase in glutaminase (a degradation target of APC/C-Cdh1), which causes an elevation of glutamate levels and further intraneuronal Ca2+ dysregulation, resulting in neuronal apoptosis. Glutaminase inhibition prevents glutamate excitotoxi…

0301 basic medicineProteasome Endopeptidase ComplexCell SurvivalAmyloid betaBlotting WesternExcitotoxicityHippocampusmedicine.disease_causeHippocampusArticleAnaphase-Promoting Complex-CyclosomeCdh1 ProteinsAnimals Genetically ModifiedMice03 medical and health sciences0302 clinical medicineGlutaminasemedicineAnimalsRats WistarNeuronsAmyloid beta-PeptidesMultidisciplinarybiologyGlutaminaseCyclin-dependent kinase 5Glutamate receptorCyclin-Dependent Kinase 5Molecular biologyRatsUbiquitin ligase030104 developmental biologyApoptosisbiology.protein030217 neurology & neurosurgeryScientific Reports
researchProduct